Advertisement

Topics

Myeloma-Developing Regimens Using Genomics (MyDRUG)

2018-11-12 18:20:23 | BioPortfolio

Published on BioPortfolio: 2018-11-12T18:20:23-0500

Clinical Trials [1277 Associated Clinical Trials listed on BioPortfolio]

Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma

This phase I/II trial studies the side effects and best dose of clarithromycin when given together with ixazomib citrate, pomalidomide, and dexamethasone and to see how well it works in tr...

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

The purpose of this study is to determine the efficacy of Ixazomib when combined with Pomalidomide and Dexamethasone, in terms of overall response rate in subjects with relapsed Multiple M...

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.

IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic

This study is a Multicenter, Open-label, Phase II study of ixazomib, plus Pomalidomide and Dexamethasone regimen (IPD) in RRMM with adverse Genomic Abnormalities.

Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma

This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or doe...

PubMed Articles [270 Associated PubMed Articles listed on BioPortfolio]

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Novel efficacious treatments with long-term tolerability are needed for transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. This phase 2 study evaluated the safety and efficacy of...

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory a...

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Following the publication of this article, the authors noted that the pomalidomide dose for the additional SC cohort in Fig. 1 was incorrectly listed. The correct dose for pomalidomide in the addition...

Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.

Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells.

Ixazomib (Ninlaro), a novel proteasome inhibitor, has been developed for the treatment of many cancers and has demonstrated anti-tumor efficacy against various malignancies. However, the mechanism of ...

Medical and Biotech [MESH] Definitions

An anti-inflammatory 9-fluoro-glucocorticoid.

An anti-inflammatory, anti-allergic glucocorticoid that can be administered orally, by inhalation, locally, and parenterally. It may cause water and salt retention.

A member of the TNF receptor family that was initially identified as a DEXAMETHASONE-induced protein from a T-CELL line. It may play a role in regulating APOPTOSIS and modulating immune response by T-lymphocytes. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.

More From BioPortfolio on "Myeloma-Developing Regimens Using Genomics (MyDRUG)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial